NoneTEL AVIV, Israel (AP) — Israel said Sunday that the body of an Israeli-Moldovan rabbi who went missing in the United Arab Emirates has been found after he was killed in what it described as a “heinous antisemitic terror incident.” The UAE's Interior Ministry later said authorities arrested three suspects involved in the killing of Zvi Kogan. The statement from Prime Minister Benjamin Netanyahu's office said Israel “will act with all means to seek justice with the criminals responsible for his death.” Israeli authorities did not say how they determined the killing of Kogan was a terror attack and offered no additional details. Kogan, 28, an ultra-Orthodox rabbi who went missing on Thursday, ran a kosher grocery store in the futuristic city of Dubai, where Israelis have flocked for commerce and tourism since the two countries forged diplomatic ties in the 2020 Abraham Accords . The agreement has held through more than a year of soaring regional tensions unleashed by Hamas' Oct. 7, 2023 attack into southern Israel . But Israel's devastating retaliatory offensive in Gaza and its invasion of Lebanon, after months of fighting with the Hezbollah militant group, have stoked anger among Emiratis, Arab nationals and others living in the the UAE. Iran, which supports Hamas and Hezbollah, has also been threatening to retaliate against Israel after a wave of airstrikes Israel carried out in October in response to an Iranian ballistic missile attack. The Emirati government did not respond to a request for comment. However, senior Emirati diplomat Anwer Gargash wrote on the social platform X in Arabic on Sunday that “the UAE will remain a home of safety, an oasis of stability, a society of tolerance and coexistence and a beacon of development, pride and advancement.” Early on Sunday, the UAE’s state-run WAM news agency acknowledged Kogan’s disappearance but pointedly did not acknowledge he held Israeli citizenship, referring to him only as being Moldovan. The Emirati Interior Ministry described Kogan as being “missing and out of contact.” “Specialized authorities immediately began search and investigation operations upon receiving the report,” the Interior Ministry said. The ministry later said that three “perpetrators” had been arrested “in record time” without giving additional details. Netanyahu told a regular Cabinet meeting later Sunday that he was “deeply shocked” by Kogan's disappearance and death. He said he appreciated the cooperation of the UAE in the investigation and that ties between the two countries would continue to be strengthened. Israel's largely ceremonial president, Isaac Herzog, condemned the killing and thanked Emirati authorities for "their swift action." He said he trusts they “will work tirelessly to bring the perpetrators to justice.” Israel also again warned against all nonessential travel to the Emirates after Kogan's killing. “There is concern that there is still a threat against Israelis and Jews in the area,” a government warning issued Sunday said. Kogan was an emissary of the Chabad Lubavitch movement, a prominent and highly observant branch of ultra-Orthodox Judaism based in Brooklyn's Crown Heights neighborhood in New York City. It said he was last seen in Dubai. The UAE has a burgeoning Jewish community, with synagogues and businesses catering to kosher diners. The Rimon Market, a kosher grocery store that Kogan managed on Dubai’s busy Al Wasl Road, was shut Sunday. As the wars have roiled the region, the store has been the target of online protests by supporters of the Palestinians. Mezuzahs on the front and back doors of the market appeared to have been ripped off when an Associated Press journalist stopped by on Sunday. Kogan’s wife, Rivky, is a U.S. citizen who lived with him in the UAE. She is the niece of Rabbi Gavriel Holtzberg, who was killed in the 2008 Mumbai attacks. The UAE is an autocratic federation of seven sheikhdoms on the Arabian Peninsula and is also home to Abu Dhabi. Local Jewish officials in the UAE declined to comment. While the Israeli statement did not mention Iran, Iranian intelligence services have carried out past kidnappings in the UAE. Western officials believe Iran runs intelligence operations in the UAE and keeps tabs on the hundreds of thousands of Iranians living across the country. Iran is suspected of kidnapping and later killing British Iranian national Abbas Yazdi in Dubai in 2013, though Tehran has denied involvement. Iran also kidnapped Iranian German national Jamshid Sharmahd in 2020 from Dubai, taking him back to Tehran, where he was executed in October . Gambrell reported from Dubai, United Arab Emirates
Ahilyabai hailed for pro-women stanceAI warfare may conjure images of killer robots and autonomous drones, but a different reality is unfolding in the Gaza Strip. There, artificial intelligence has been suggesting targets in Israel’s retaliatory campaign to root out Hamas following the group’s Oct. 7, 2023 attack. A program known as “The Gospel” generates suggestions for buildings and structures militants may be operating in. “Lavender” is programmed to identify suspected members of Hamas and other armed groups for assassination, from commanders all the way down to foot soldiers. “Where’s Daddy?” follows their movements by tracking their phones in order to target them—often to their homes, where their presence is regarded as confirmation of their identity. The air strike that follows might kill everyone in the target's family, if not everyone in the apartment building. These programs, which the Israel Defense Force (IDF) has acknowledged developing, may help explain the pace of the most devastating bombardment campaign of the 21st century, in which more than 44,000 Palestinians have been killed, according to the Hamas-run Gaza Health Ministry, whose count is regarded as reliable by the U.S. and U.N. In earlier Gaza wars, Israeli military veterans say airstrikes occurred at a much slower tempo. “During the period in which I served in the target room [between 2010 and 2015], you needed a team of around 20 intelligence officers to work for around 250 days to gather something between 200 to 250 targets,” Tal Mimran, a lecturer at Hebrew University in Jerusalem and a former legal adviser in the IDF, tells TIME. “Today, the AI will do that in a week.” Experts on the laws of war, already alarmed by the emergence of AI in military settings, say they are concerned that its use in Gaza, as well as , may be establishing dangerous new norms that could become permanent if not challenged. The treaties that govern armed conflict are non-specific when it comes to the tools used to deliver military effect. The elements of international law covering war—on proportionality, precautions, and distinctions between civilians and combatant—apply whether the weapon being used is a crossbow or a tank—or an AI-powered database. But some advocates, including the International Committee of the Red Cross, , noting the crucial need to ensure human control and accountability as AI weapons systems become more advanced. “The pace of technology is far outstripping the pace of policy development,” says , the executive vice president at the Center for a New American Security and the author of . “It’s quite likely that the types of AI systems that we’ve seen to date are pretty modest, actually, compared to ones that are likely to come in the near future.” The AI systems the IDF uses in Gaza were first detailed a year ago on the Israeli online news outlet , which shared its reporting with . Yuval Abraham, the Israeli journalist and filmmaker behind the investigation, tells TIME he believes the decision to “bomb private houses in a systemic way” is “the number one factor for the civilian casualties in Gaza.” That decision was made by humans, he emphasizes, but he says AI targeting programs enabled the IDF “to take this extremely deadly practice and then multiply it by a very large scale.” Abraham, whose report relies on conversations with six Israeli intelligence officers with first-hand experience in Gaza operations after Oct. 7, quoted targeting officers as saying they found themselves deferring to the Lavender program, despite knowing that it produces incorrect targeting suggestions in roughly 10% of cases. One intelligence officer tasked with authorizing a strike recalled dedicating roughly 20 seconds to personally confirming a target, which could amount to verifying that the individual in question was male. The Israeli military, in responding to the report, said that its use of AI is misunderstood, saying in a that Gospel and Lavender merely “help intelligence analysts review and analyze existing information. They do not constitute the sole basis for determining targets eligible to attack, and they do not autonomously select targets for attack.” At a conference in Jerusalem in May, one senior military official sought to minimize the importance of the tools, which he likened to “glorified Excel sheets,” Mimran and another person in attendance told TIME. The IDF did not specifically dispute Abraham’s reporting about Lavender’s 10% error rate, or that an analyst might spend as little as 20 seconds analyzing the targets, but in a statement to TIME, a spokesperson said that analysts “verify that the identified targets meet the relevant definitions in accordance with international law and additional restrictions stipulated in the IDF directives.” Converting data into target lists is not incompatible with the laws of war. Indeed, a scholar at West Point, assessing the Israeli programs, that more information could make for greater accuracy. By , that may have been the case the last time Israel went to war in Gaza, in 2021. That brief conflict apparently marked the first time the IDF used artificial intelligence in a war, and afterward, the then-head of UNRWA, the U.N. agency that provides health, education, and advocacy for Palestinians, on “a huge sophistication in the way the Israeli military struck over the last 11 days.” But the 2021 round of combat, which produced 232 Palestinian deaths, was a different kind of war. It was fought under Israeli rules of engagement ostensibly intended to minimize civilian casualties, including by "knocking on the door"—dropping a small charge on the rooftop of a building to warn occupants that it was about to be destroyed, and should evacuate. In the current war, launched more than 14 months ago to retaliate for the worst attack on Jews since the Holocaust, Israeli leaders shut off water and power to all of Gaza, launched 6,000 airstrikes in the space of , and suspended some measures intended to limit civilian casualties. "This time we are not going to " " and ask them to evacuate the homes," former Israeli military intelligence chief Amos Yadlin five days after Oct. 7, warning that that the weeks ahead would be "very bloody" in Gaza. "We are going to attack every Hamas operative and especially the leaders and make sure that they will think twice before they will even think about attacking Israel." Abraham reported that targeting officers were told it was acceptable to kill 15 to 20 noncombatants in order to kill a Hamas soldier (the number in previous conflicts, he reports, was zero), and as many as 100 civilians to kill a commander. The IDF did not comment on those figures. Experts warn that, with AI generating targets, the death toll may climb even higher. They cite “automation bias”—the presumption that information provided by AI is accurate and reliable unless proven otherwise, rather than the other way around. Abraham says his sources reported times they made just that assumption. “Yes there is a human in the loop,” says Abraham, “but if it’s coming at a late stage after decisions have been made by AI and if it is serving as a formal rubber stamp, then it’s not effective supervision.” Former IDF chief offered a similar observation in an with the Israeli news site Ynet six months before Oct. 7. “The concern,” he said, speaking of AI broadly, “is not that robots will take control over us, but that artificial intelligence will supplant us, without us even realizing that it is controlling our minds.” Adil Haque, the executive editor of the national security law blog Just Security and the author of , described the tension at play. “The psychological dynamic here pushes against the legal standard,” he says. “Legally, the presumption is that you can’t attack any person unless you have very strong evidence that they’re a lawful target. But psychologically, the effect of some of these systems can be to make you think that this individual is a lawful target, unless there’s some very obvious indication that you make independently that they are not.” Israel is far from the only country using artificial intelligence in its military. Scores of defense tech companies operate in Ukraine, where the software developed by the Silicon Valley firm Palantir Technologies “is responsible for most of the targeting” against Russia, its CEO TIME in 2023, describing programs that present commanders with targeting options compiled from satellites, drones, open-source data, and battlefield reports. As with Israel, experts that Ukraine’s use of AI is in a “predominantly supportive and informational role,” and that the kinds of technology being trialed, from AI-powered artillery systems to AI-guided drones, are not yet fully autonomous. But concerns abound about potential misuse, particularly on issues related to accuracy and privacy. Anna Mysyshyn, an AI policy expert and director of the Institute of Innovative Governance, an NGO and watchdog of the Ministry of Digital Transformation of Ukraine, tells TIME that while “dual-use technologies” such as the facial-recognition system Clearview AI play an important role in Ukraine’s defense, concerns remain about their use beyond the war. “We’re talking about ... how to balance between using technologies that have advantages on the battlefield [with] protecting human rights,” she says, noting that “regulation of these technologies is complicated by the need to balance military necessity with civilian protection.” With fighting largely confined to battlefields, where both Russian and Ukrainian forces are dug in, the issues that animate the debate in Gaza have not been in the foreground. But any country with an advanced military—including the U.S.—is likely to soon confront the issues that come with machine learning. “Congress needs to be prepared to put guardrails on AI technologies—especially those that put international humanitarian law in question and threaten civilians,” Sen. Peter Welch of Vermont said in a statement to TIME. In September, he and Sen. Dick Durbin of Illinois to Secretary of State Antony Blinken urging the State Department to “proactively and publicly engage in setting international norms about the ethical deployment of AI technology.” Welch has also since put forward his proposed Artificial Intelligence Weapons Accountability and Risk Evaluation (AWARE) Act, which if passed would require the Defense Department to catalog domestic deployments of AI systems, the risks associated with them, and any foreign sharing or exportation of these technologies. “A more comprehensive and public approach is necessary to address the risk of AI weapons and maintain America’s leadership in ethical technology development,” Welch says, “as well as establish international norms in this critical space.” It may seem unlikely that any government would find an incentive to introduce restrictions that also curtail its own military’s advancements in the process. “We’ve done it before,” counters Alexi Drew, a Technology Policy Adviser at the ICRC, pointing to treaties on disarmament, cluster munitions, and landmines. “Of course, it’s a very complex challenge to achieve, but it’s not impossible.”4 easy, comforting bean dishes for fall
‘Kudos & Willies’: Nothing nice to say about Giants-Bucs, but we’re reviewing the game, anyway - Big Blue View
NoneOne of the biggest giants in all of sports took a tumble on Sunday, as the No. 1 South Carolina women's basketball team had its 43-game win streak snapped with a 77-62 upset loss to No. 5 UCLA. The loss dropped the Gamecocks to 5-1 this season, while the Bruins remained undefeated at 5-0 and could rise up the Top 25 following Sunday's monumental victory. This article will be updated soon to provide more information and analysis. For more from Bleacher Report on this topic and from around the sports world, check out our B/R app , homepage and social feeds—including Twitter , Instagram , Facebook and TikTok .
One of the biggest giants in all of sports took a tumble on Sunday, as the No. 1 South Carolina women's basketball team had its 43-game win streak snapped with a 77-62 upset loss to No. 5 UCLA. The loss dropped the Gamecocks to 5-1 this season, while the Bruins remained undefeated at 5-0 and could rise up the Top 25 following Sunday's monumental victory. This article will be updated soon to provide more information and analysis. For more from Bleacher Report on this topic and from around the sports world, check out our B/R app , homepage and social feeds—including Twitter , Instagram , Facebook and TikTok .Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Option Care Health, Inc. ( NASDAQ:OPCH – Free Report ) by 438.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 145,257 shares of the company’s stock after buying an additional 118,292 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.09% of Option Care Health worth $4,547,000 at the end of the most recent quarter. Several other large investors have also bought and sold shares of the business. CANADA LIFE ASSURANCE Co lifted its stake in shares of Option Care Health by 1.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 134,305 shares of the company’s stock valued at $4,503,000 after purchasing an additional 2,355 shares during the period. CreativeOne Wealth LLC lifted its stake in Option Care Health by 24.9% in the first quarter. CreativeOne Wealth LLC now owns 10,885 shares of the company’s stock valued at $365,000 after buying an additional 2,173 shares during the period. BOKF NA boosted its holdings in Option Care Health by 13.5% during the first quarter. BOKF NA now owns 47,139 shares of the company’s stock worth $1,546,000 after buying an additional 5,589 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Option Care Health by 1.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,760,482 shares of the company’s stock worth $59,047,000 after buying an additional 23,676 shares during the period. Finally, Janus Henderson Group PLC increased its stake in shares of Option Care Health by 182.9% in the 1st quarter. Janus Henderson Group PLC now owns 227,135 shares of the company’s stock valued at $7,617,000 after acquiring an additional 146,837 shares during the last quarter. 98.05% of the stock is currently owned by institutional investors and hedge funds. Option Care Health Trading Up 2.8 % OPCH opened at $23.13 on Friday. The stock has a market capitalization of $3.94 billion, a P/E ratio of 19.44, a P/E/G ratio of 2.33 and a beta of 1.32. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. Option Care Health, Inc. has a 12 month low of $21.39 and a 12 month high of $34.63. The firm’s fifty day simple moving average is $27.62 and its 200 day simple moving average is $29.10. Insider Activity Analysts Set New Price Targets Several research firms recently weighed in on OPCH. Barrington Research reduced their price objective on shares of Option Care Health from $40.00 to $32.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. JMP Securities lifted their price target on shares of Option Care Health from $36.00 to $37.00 and gave the stock a “market outperform” rating in a research report on Monday, September 30th. Truist Financial lowered their price objective on shares of Option Care Health from $41.00 to $34.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Jefferies Financial Group lowered Option Care Health from a “buy” rating to a “hold” rating and reduced their target price for the stock from $38.00 to $26.00 in a report on Thursday, October 31st. Finally, Bank of America cut Option Care Health from a “buy” rating to a “neutral” rating and decreased their target price for the company from $43.00 to $29.00 in a research note on Wednesday, October 30th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Option Care Health has a consensus rating of “Moderate Buy” and an average price target of $30.83. View Our Latest Stock Report on Option Care Health Option Care Health Profile ( Free Report ) Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. Featured Stories Want to see what other hedge funds are holding OPCH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Option Care Health, Inc. ( NASDAQ:OPCH – Free Report ). Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with MarketBeat.com's FREE daily email newsletter .
ATHENS Romanian Premier Marcel Ciolacu led the first round of Sunday's presidential election with 25% votes, exit polls showed, and a run-off seemed likely after two weeks. Ciolacu, candidate of the Social Democratic Party, was followed by Elena Lasconi of the Save Romania Union party with 18%, the Antena3 broadcaster reported. Some 9.4 million people cast vote in the polls that closed at 1900 GMT, indicating an over 50% voter turnout. Voters were choosing between 13 candidates to replace outgoing President Klaus Iohannis. The top two move on to a run-off on Dec. 8 if no single candidate gets more than 50% of the vote in the first round.
(TNS) — Jeff Borland came to one of his students in January 2021 with an idea. The Deering High School computer science and statistics teacher wanted to create a better way for Portland teachers to communicate with families in many languages. "Deering is a very diverse school; there's something like 50 languages spoken. There were platforms that allowed us to contact families with translation, but they all, it seemed, had limitations," Borland said. "It seemed like it could be better." He got his computer whiz student Aidan Blum Levine on board, and together they created ReachMyTeach, a website that allows teachers to write messages in English that automatically get translated into parents' preferred languages and can be delivered via email, text or WhatsApp. Any responses are translated into English. The program supports more than 200 languages, and is also a helpful hub for communicating with English-speaking families. It is now universal in Portland Public Schools, for both teachers and the district office. In the last four years, ReachMyTeach has seen massive growth. More than 2 million messages were shared through the platform in November, and it's now in use in 40 Maine school districts, nine states and one international school. Borland enjoyed coding on the side and knew that his student Blum Levine, now a senior at the Massachusetts Institute of Technology in Cambridge, had essentially exhausted his class options and had some free time. They wanted to create a better, more consolidated platform for teachers and parents to communicate across languages. As a teacher, Borland was aware of the district's growing multilingual population. In 2021, there were 1,484 English learners in Portland schools; by 2024, that number had grown to 2,002 — more than a quarter of all students. Borland and Blum Levine coded the site over February break and pitched it to Deering administrators in March. An early version went into use at the high school that spring. By the summer of 2021, Borland and Blum Levine received an investment from the education company Faria Education Group. Borland took six months off from teaching to develop the program. Borland said the local origins of ReachMyTeach were integral to its early development. One early change was adding a WhatsApp option because Deering teachers said that was necessary to reach all parents. WhatsApp is a free app that doesn't require cellphone data and is widely used outside of the United States and by immigrants in the country. "We were constantly, that spring, adding and adding until it was more robust. It was literally all from teacher comments and feedback, and from families," he said. Kailen Kennedy is a kindergarten teacher at Presumpscot Elementary School and previously taught elementary-age English Language Learners. Kennedy has been using ReachMyTeach since the fall of 2022 and described it as a "game changer." She said she previously relied on interpreters, which would sometimes take days to set up. "I think it affected the types of relationships I had with families," she said. "I feel like now, I can reach everyone, at one time." ReachMyTeach is connected to the school's attendance software, which makes mass parent emails much smoother. Kennedy said there were some growing pains, but the product has drastically improved over time, and the creators are very open to feedback. Now, Kennedy uses it for everything from setting up conferences to letting parents know they should send their kids to school with snow pants. Nearly half of her 21 students come from families that rely on translation, and ReachMyTeach improves equity and access. "It's leveled the playing field with who we communicate with, and how we communicate with them," she said. It's also a time saver. "Before ReachMyTeach, it was just a more daunting task to reach out to families, because there were just so many more steps," said King Middle School English teacher Chris Pirkl. Pirkl said the software has revolutionized communication with parents who don't speak English. Previously, he said, before sending any mass email to parents, he would need to manually run it through Google Translate six or seven times to get different translations. Pirkl was part of the beta test for the new ReachMyTeach cellphone app and has used a new feature that allows teachers to send bulk emails that autofill with students' names. The new version also suggests better word choices that will translate more cleanly. Kennedy and Pirkl both said they're proud that the product was created by fellow Portland teachers. "They've built this thing that not only is popular and successful but ultimately is just useful and practical and fills a need that existed," Pirkl said. Helen Cohen was a fellow Deering High teacher who taught history and English language learners before she joined the ReachMyTeach team in June 2022 as the CEO. Borland returned to the classroom, Blum Levine continued his studies at college and Cohen took the reins. While ReachMyTeach has become ubiquitous in Portland schools, it's also available in dozens of other school districts. The company also works with a few nonprofits that have similar translation needs to schools. "What works well for multilingual families works really well for English-speaking families," Cohen said. "And if you can have everything in one place, no one slips through the cracks." The platform is still growing. The company recently hired its first full-time sales person and is still making major product improvements, like partnering with the company Lexikeet Language Services to provide live interpreters for districts that don't have translators on staff. ReachMyTeach uses Google Translate for a lot of its translations, as well as other machine translation services. But the company is now working with native speakers to improve the smoothness of the translation, especially for languages like Lingala and Somali that aren't well accommodated my machine translation. Blum Levine said it's cool to observe from a distance as his younger sister and parents now use the product. "We were kind of just making this for something to do, and we thought it would maybe get used by a few people. And then the feedback we've gotten, and how quickly it's grown, has been amazing," Blum Levine said. Borland is only teaching part-time these days so he can remain involved in the company. Blum Levine is graduating from MIT a semester early and said he'll spend the next six months working on the platform "pretty full time." Although he's focused on ReachMyTeach now, Blum Levine said the experience has prepared him for future endeavors. "I have learned a lot, and not just focused on like the coding skills side, but looking more holistically at how you make a successful startup," he said. "If in the future I did have an idea that I was excited about, I feel like this has been like an invaluable experience, learning skills useful for that."
We're in the back-half of the NFL season as we enter the beloved Thanksgiving Week of games, and the playoff picture is starting to become more and more clear. While teams like the Detroit Lions, Kansas City Chiefs, Buffalo Bills, and Philadelphia Eagles should feel solid in their postseason standings, there are other teams on the bubble who are fighting for their playoff lives each and every week. One of those teams has caught the eye of notorious podcaster Bill Simmons, the owner of The Ringer. On his show this Sunday with 'Cousin Sal' Iacono, Simmons declared that there is a rookie QB in the AFC that is making waves, and he wouldn't want to bet against him in the postseason if they ended up making it that far. (Ron Chenoy-Imagn Images) That rookie QB is Bo Nix, who has the Denver Broncos sitting at 7-5 after an impressive win over the Las Vegas Raiders on Sunday afternoon. "I feel like I've watched a lot of the Broncos because they have these afternoon games on the West Coast, and first of all, Nix has gotten night-and-day better from that Jets game where he threw for 60 yards," Simmons said. "It's like a different human being." Over the last two months, Nix has come into his own as a rookie passer, racking up 19 touchdowns to just 2 interceptions in the past 10 weeks. While he was the last of six QBs to be drafted in the first round back in April, it's becoming apparent that the former Oregon Duck is playing just as well, if not better than any rookie in this QB class. More than just his play, though, it's the demeanor of Nix that grabbed Simmons' eye. "He's kind of a bad-ass, like he talks (expletive,)" Simmons said. "They had that replay today and he was just screaming at the defensive lineman for the other team. Granted, he's like a 30-year-old rookie — he's like Scott Bakula in 'Unnecessary Roughness' — but he doesn't carry himself like a rookie." Bo Nix isn’t afraid of ANYBODY 😳 The Broncos have themselves a LEADER. pic.twitter.com/JiremLwV9q While the Broncos had a slow start to the season, they've come on strong as of late and are making a real push to get into the postseason. At the moment, they currently sit in 7th place in the AFC, but have a good schedule moving forward, with games against the Cleveland Browns, Indianapolis Colts, Los Angeles Chargers, Cincinnati Bengals, and a Kansas City Chiefs team that could potentially be resting starters in Week 18. "I don't know, I can see them in the playoffs," Simmons said. "And if they were in the playoffs, I wouldn't be like 'Oh I can't wait to bet against Denver.' I think they're pretty frisky." Related: Colin Cowherd Makes Bold 5-Word Statement About Broncos QB Bo Nix
Pacers push to build momentum, take advantage of bruised Blazers
Gretchen McKay | (TNS) Pittsburgh Post-Gazette Beans are kind of like the your best friend from high school — nearly forgotten but always ready to step back into the limelight and help out an old pal when needed. As gorgeously (and tantalizingly) demonstrated in Rancho Gordo’s new cookbook, “The Bean Book: 100 Recipes for Cooking with All Kinds of Beans” (Ten Speed, $35), beans are indeed a magical fruit, though not in the way you heard as a kid. Classified as both a vegetable and a plant-based protein in the USDA’s Dietary Guidelines for Americans, beans and other legumes can be the ingredient you build an entire vegetarian or veggie-forward meal around. Or, they can help an economical cook stretch a dish twice as far with nutritious calories. A healthful and shelf-staple plant food — they last for years when dried — beans have been among a home cook’s most reliable pantry items for a very long time. (Common beans (Phaseolus vulgaris) are thought to have been grown in Mexico more than 7,000 years ago.) That’s why, for some, they’re often something of an afterthought, especially if the only time you ate them as a kid was when your mom tossed kidney beans into a pot of beef chili or made baked beans (with brown sugar and bacon, please!) for a family cookout. Vegetarians have always appreciated their versatility and nutritional punch, and because they’re cheap, they also were quite popular during the Great Depression and World War II as C rations. Sales also peaked during the coronavirus pandemic, when shoppers stockpiled long-lasting pantry essentials. It wasn’t until Rancho Gordo, a California-based bean company, trotted out its branded packages of colorful heirloom beans that the plant began to take on cult status among some shoppers. Unlike the bean varieties commonly found in even the smallest grocery stores, heirloom beans are mostly forgotten varieties that were developed on a small scale for certain characteristics, with seeds from the best crops passed down through the generations. The result is beans that are fresher and more colorful than mass-produced beans, and come in different shapes and sizes. They also have a more complex and intense flavor, fans say. “The Bean Book” dishes up dozens of different ways to cook Rancho Gordo’s 50 heirloom bean varieties, which include red-streaked cranberry beans, mint-green flageolets, black and classic garbanzos and (my favorite) vaquero — which wear the same black-and-white spots as a Holstein cow. Other gotta-try varieties (if just for the name) include eye of the goat, European Soldier, Jacob’s Cattle and Good Mother Stallard, a purple bean with cream-colored flecks. “The very good news is that you have to work extra hard to mess up a pot of beans, and it’s not difficult to make an excellent pot,” Steve Sando writes in the book’s foreword. “The even better news is that you become a better cook with each pot you make.” Not convinced? Here are five reasons to jump on the bean bandwagon: They’re easy to find Even the smallest grocery store will have a selection of dried and canned beans. Common varieties include black, cannellini (white kidney), Great Northern, pinto, navy, kidney, Lima and garbanzo (chickpea) beans. They’re affordable Even when they’re not on sale, beans are a bargain at the supermarket. Many varieties cost less than $1 a can, and dried beans are an economical way to build a menu. I paid $1.25 for a one-pound bag of cranberry beans, a smooth and velvety bean with a slightly nutty flavor, at my local grocery store. Rancho Gordo’s heirloom beans cost substantially more. (They run $6.25-$7.50 for a one-pound bag, with free shipping on orders over $50.) But they are sold within a year of harvest, which makes them more flavorful and tender. A bag also comes with cooking instructions and recipe suggestions, and the quality is outstanding. Plus, after cooking their beans with aromatics, “you are left with essentially free soup,” Sando writes in the cookbook. “If you drain properly cooked and seasoned beans, the liquid you are left with is delicious.” They’re nutritious Beans are a great source of plant-based protein and both soluble and insoluble fiber, and they include essential minerals like iron, magnesium and potassium. If you’re watching your weight or following a particular diet, beans are naturally free of fat, sodium and cholesterol and are rich in complex carbohydrates. They also contain antioxidants and folate. And if you’re vegan or vegetarian, most types of dry beans are rich sources of iron. The U.S. Dietary Guidelines for Americans recommends eating 1-3 cups of legumes, including beans, per week They’re a cinch to cook Dry beans have to be soaked overnight, but cooking them is easy. They can be cooked on the stovetop, in a slow cooker, in the pressure cooker and in the oven. Canned beans are even easier — just rinse and drain, and they’re ready to go. They’re versatile Beans can be used in so many different dishes. They can be made into soup, salad or dips, top nachos, add some heft to a casserole or be mashed into the makings of a veggie burger. You also can add them to brownies and other baked goods, toss them with pasta, add them to chili or a rice bowl or stuff them into a taco or burrito. Check out these four recipes: White Bean Soup with Shiitake Bacon PG tested This light and creamy vegetarian soup benefits from a surprising garnish, roasted shiitake mushrooms, which taste exactly like bacon. For soup 1/4 cup olive oil 1 medium yellow onion, chopped 2 celery stalks, chopped 1 medium carrot, scrubbed and chopped 6 garlic cloves, finely grated or pressed 2 sprigs fresh thyme, plus more for garnish 1/2 teaspoon sea salt 1/4 teaspoon pepper 4 cups vegetable broth 2 15-ounce cans cannellini beans, drained and rinsed For bacon 8 ounces shiitake mushrooms, caps cut into 1/8 -inch slices 2 tablespoons olive oil 1/4 teaspoons fine sea salt To finish Plant-based milk Chili oil, for drizzling Preheat oven to 400 degrees. Make soup: In large pot, heat oil over medium heat until it shimmers. Add onion, celery, carrot, garlic, thyme, salt and pepper. Cook, stirring occasionally, until vegetables are fragrant and tender, 8-10 minutes. Add vegetable stock and beans, increase heat to high and bring mixture to a boil. Reduce heat to medium and simmer until thickened, 12-14 minutes. Meanwhile, make the bacon: Spread shiitake mushrooms into a single layer on a sheet pan, drizzle with olive oil, sprinkle with salt and pepper and toss to combine. Bake until browned and crispy, 18-20 minutes, rotating pan front to back and tossing mushrooms with a spatula halfway through. Let cool in pan; mushrooms will continue to crisp as they cool. To finish, add some milk to the soup and use an immersion blender to puree it in the pot, or puree in a blender. (Cover lid with a clean kitchen towel.) Taste and season with more salt and pepper if needed. Divide soup among bowls and top with shiitake bacon. Garnish with thyme sprigs and a drizzle of chili oil. Serves 4-6. — “Mastering the Art of Plant-Based Cooking” by Joe Yonan Polenta with Cranberry Beans and Tomato Sauce PG tested Velvety cranberry beans simmered with tomato and the punch of red wine vinegar are a perfect match for a soft bed of cheesy polenta. This is a filling, stick-to-your-ribs dish perfect for fall. 1/4 cup olive oil 1 small onion, finely chopped 2 garlic cloves, minced 2 cups canned chopped tomatoes, juice reserved 1 tablespoon red wine vinegar 2 tablespoons tomato paste 1 cup chicken or vegetable broth 4 fresh sage leaves Salt and pepper 4 cups cooked Lamon or cranberry beans 2 cups uncooked polenta 6 ounces pancetta, diced Chopped fresh basil or parsley, for garnish Grated Parmesan cheese, for serving In large pan, heat olive oil over medium heat. Add onion and garlic and cook, stirring, until onion begins to soften, about 3 minutes. Stir in tomatoes and red wine vinegar. In a small bowl, dissolve tomato paste in the broth and add to pan. Stir in sage and season with salt and pepper. Simmer, stirring occasionally, until the sauce has thickened, 15-20 minutes. Add beans to tomato sauce. Cook, stirring frequently, until heated through, about 15 minutes. Meanwhile, prepare polenta according to package instructions. Place pancetta in a small saucepan over low heat. Cook, stirring frequently, until the pancetta is brown and crisp, about 15 minutes. Use a slotted spoon to transfer pancetta to a paper towel to drain. To serve, spoon polenta into serving dishes. Ladle the beans over the polenta and top with the pancetta. Garnish with fresh basil and serve with grated Parmesan. Serves 6. — “The Bean Book: 100 Recipes for Cooking with All Kinds of Beans” by Steve Sando White Beans with Clams and Chorizo PG tested Beans and seafood might seen like an unusual pairing, but in this recipe, mild white beans take on a lot of flavor from clams. Spanish chorizo adds a nice contrast. 4 cups cooked white beans, bean broth reserved 1/4 cup extra-virgin olive oil 1/2 white onion, chopped 2 garlic cloves, chopped 1 teaspoon salt, or to taste 1/2 cup finely chopped Spanish-style cured chorizo 2 plum tomatoes, chopped 1/2 cup dry white wine 2 pounds small clams, scrubbed well Chopped fresh parsley, for garnish Country-style bread and butter, for serving In large pot, heat beans in their broth over medium-low heat. In large lidded saucepan, warm olive oil over medium-low heat. Add onion, garlic and salt and cook until soft, about 5 minutes. Add chorizo and cook gently until some of the fat has rendered, about 5 minutes. Add tomatoes and wine and cook to allow the flavors to mingle, 5-6 minutes. Increase heat to medium and add clams. Cover and cook for about 5 minutes, shaking the pan occasionally. Uncover the pan and cook until all of the clams open, another few minutes. Remove pan from heat, then remove and discard any clams that failed to open. Add clam mixture to the bean pot and stir very gently until well mixed. Simmer for a few minutes to allow the flavors to mingle but not get mushy. Ladle into large, shallow bowls and sprinkle with parsley. Set out a large bowl for discarded shells and encourage guests to eat with their fingers. Pass plenty of good bread and creamy butter at the table Serves 4-6. — “The Bean Book: 100 Recipes for Cooking with All Kinds of Beans, from the Rancho Gordo Kitchen” by Steve Sando with Julia Newberry White Bean Dip PG tested So easy to pull together for your next party! 1 1/2 cups cooked cannellini beans, drained and rinsed 2 tablespoons extra-virgin olive oil Juice and zest of 1 lemon 1 small garlic clove, minced Generous pinch of salt Freshly ground black pepper 2 or 3 tablespoons water, if needed 2 fresh basil leaves, chopped, optional 1 sprig fresh rosemary, leaves chopped, optional In a food processor, pulse cannellini beans, olive oil, lemon juice and zest, garlic, salt and several grinds of pepper until combined. If it’s too thick, slowly add the water with the food processor running until it is smooth and creamy. Blend in the basil and/or rosemary, if using Serve with veggies, pita or bruschetta. Makes 1 1/2 cups — Gretchen McKay, Post-Gazette ©2024 PG Publishing Co. Visit at post-gazette.com. Distributed by Tribune Content Agency, LLC.Cash and cash equivalents at €13.9 million, as of September 30, 2024. Revenues of €1.3 million for the first nine months of 2024. On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1 million. Considering the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the equity raise announced on October 14, 2024 2 and the receipt of the $10 million milestone payment under the amended license and collaboration agreement with CTTQ on November 18, 2024, the Company estimates that its cash, cash equivalents and deposits would enable it to finance its operations until the end of the second quarter of 2025 3 . Daix (France), New York City, (New York, United States), November 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today reported its cash position as of September 30, 2024 and its revenues for the first nine months of 2024. Cash and cash equivalents As of September 30, 2024, the Company’s cash and cash equivalents amounted to €13.9 million, compared to cash and cash equivalents at €26.9 million, short-term deposit 4 at €0.01 million, and long-term deposit 5 at €9.0 million as of December 31, 2023. Net cash used in operating activities amounted to (€64.2) million in the first nine months of 2024, compared to (€69.0) million for the same period in 2023 down by 7.0%. R&D expenses, mainly driven by the development of lanifibranor in MASH/NASH, for the first nine months of 2024 amounted to €71.7 million and were down 10.0% compared to the €79.6 million for the first nine months of 2023. The decrease in R&D expenses over the period is primarily due to the temporary voluntary pause in the recruitment of patients in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH/NASH (“NATiV3") following the Suspected Unexpected Serious Adverse Reaction (“SUSAR”) previously reported in the first quarter of 2024 and, to a lesser extent, due to the completion of the LEGEND Phase 2a combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and type 2 diabetes (“T2D”). R&D expenses have started to increase as expected in the second half of 2024 following the restart of patient recruitment in NATiV3, as well as the planned clinical development activities and related costs associated with the NATiV3 for the second half of 2024. Net cash generated from investing activities for the first nine months of 2024 amounted to €8.7 million, compared to (€3.5) million used for the same period in 2023. The change is mostly due to the variation in term deposits between both periods. Net cash generated from financing activities for the first nine months of 2024 amounted to €42.3 million compared to €30.2 million in the same period in 2023. The change is due to (i) the second tranche of €25 million drawn in January 2024 under the unsecured loan agreement granted by the European Investment Bank (“EIB”) with the issue of 3,144,654 warrants to the EIB, and (ii) the issuance on July 18, 2024, of royalty certificates (the “2024 Royalty Certificates”) subscribed by Samsara BioCapital, and existing shareholders BVF Partners, NEA, Sofinnova, and Yiheng, for an amount of €20.1 million. The 2024 Royalty Certificates give the holders thereof the right to an annual payment of royalties equal to 3% of the potential future net sales of lanifibranor, if any, in the United States, the European Union and the United Kingdom over a 14-year term from the date of their issuance 6 . Over the first nine months of 2024, the Company did not record any exchange rate effect on cash and cash equivalents, compared to a negative exchange rate effect of (€0.7) million for the same period in 2023, due to the evolution of the EUR/USD exchange rate. Financial information after closing the accounts On October 14, 2024, the Company announced a multi-tranche equity financing (the “Equity Raise”) of up to €348 million from both new and existing investors 2 . The Company closed the first part of the first tranche of the Equity Raise on October 17, 2024, and issued 34,600,507 new ordinary shares (the “T1 New Shares”) at a price of €1.35 per T1 New Share, and 35,399,481 prefunded warrants to purchase ordinary shares in the Company at an exercise price of €0.01 and a subscription price of €1.34 per new ordinary share and received €94.1 million in gross proceeds (net proceeds approximately €86.6 million). The second part of the first tranche and the second and third tranches of the Equity Raise remain subject to satisfaction of specified conditions, and in particular shareholder approval. On October 14, 2024, the Company also announced that it had amended its license and collaboration agreement with Chia Tai Tianqing Pharmaceutical (Guangzhou) CO., LTD. (“CTTQ”). Pursuant to the amendment, if the Company receives commitments from investors to subscribe to an equity raise, in two or three tranches, prior to December 31, 2024, for an aggregate amount of at least €180 million, CTTQ shall pay to the Company (i) $10 million within 30 days of settlement-delivery of the new shares and prefunded warrants in the first tranche of the Equity Raise, (ii) $10 million upon the completion of the second tranche of the Equity Raise and (iii) $10 million upon the publication by the Company of positive topline data announcing that any key primary endpoint or key secondary endpoint of the NATiV3 trial, with any dosage regimen tested in the trial, have been met. Under the terms of the Amendment, the total amount of milestone payments remains unchanged, while the royalties that Inventiva is eligible to receive have been reduced to the low single digits. The signing of the Equity Raise satisfied the condition of receiving commitments for an aggregate amount of at least €180 million and the closing of the first part of the first tranche of the Equity Raise satisfied the condition (i) above. Subsequently, on November 18, 2024, the Company received the first milestone payment of $10 million from CTTQ pursuant to this amendment. Considering its current cost structure and forecasted expenditures and including (i) the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the Equity Raise, and (ii) the first milestone of $10 million (gross proceeds) received under the amendment to the licensing agreement with CTTQ, the Company estimates that its cash, cash equivalents and deposits would enable it to finance its operations until the end of the second quarter of 2025 2 . The Company currently expects that the conditions for the closing of the second part of the first tranche of the Equity Raise will be satisfied in December 2024. Considering its current cost structure and forecasted expenditures, the Company estimates that the anticipated receipt of the proceeds (a gross amount of €21.4 million) from the second part of the first tranche of the Equity Raise announced on October 14, 2024 would be sufficient to extend the Company’s ability to finance its operations until middle of the third quarter of 2025. Revenues The Company’s revenues for the first nine months of 2024 amounted to €1.3 million, as compared to €1.9 million for the same period in 2023. *** Next key milestones expected Randomization of the last patient of the NATiV3 Phase 3 clinical trial evaluating lanifibranor in MASH/MASH – expected in the first half 2025 following the anticipated end of screening targeted for the end of the year 2024 Topline results of NATiV3 – expected in the second half of 2026 Upcoming shareholders meeting Shareholders general meeting – December 11, 2024 Upcoming investor conference participation 43 rd Annual J.P. Morgan Healthcare conference – January 13-16, 2025 – San Francisco 13th edition of Degroof Petercam’s virtual healthcare conference – January 21-24, 2025 Upcoming scientific conference participation MASH-TAG – January 9-12, 2025 – Park City Next financial results publication Full-Year 2024 Revenues and cash and cash equivalents : Thursday, February 13, 2025 (after U.S. market close) About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate and has a pipeline of two preclinical programs. Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase 3 clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease. Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program. The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com Contacts Important Notice This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, unaudited financial information, forecasts and estimates with respect to Inventiva’s cash resources, the anticipated proceeds from the Equity Raise, completion and timing of the Equity Raise, the satisfaction in part or full of the conditions precedent to closing of the various tranches of the Equity Raise and the timing thereof, and the exercise by the investors of the warrants and pre-funded warrants issued in connection with the Equity Raise, Inventiva’s expectations regarding its collaboration agreement with CTTQ, including the achievement of specified milestones thereunder, forecasts and estimates with respect to Inventiva’s pre-clinical programs and clinical trials, including design, protocol, duration, timing, recruitment costs, screening and enrollment for those trials, including the ongoing NATiV3 Phase 3 clinical trial with lanifibranor in MASH/NASH, the clinical development of and regulatory plans and pathway for lanifibranor, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of Inventiva’s product candidates, including lanifibranor, potential regulatory submissions, approvals and commercialization, Inventiva’s pipeline and preclinical and clinical development plans, the potential development of and regulatory pathway for odiparcil, future activities, expectations, plans, growth and prospects of Inventiva and its partners, and business and regulatory strategy, the potential commercialization of lanifibranor and achievement of any sales related thereto, potential payment of royalties and anticipated future performance. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “designed”, “hopefully”, “target”, “potential”, “opportunity”, “possible”, “aim”, and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that interim data or data from any interim analysis of ongoing clinical trials may not be predictive of future trial results, the recommendation of the DMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on enrollment or the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva’s ability to obtain financing and to enter into potential transactions and Inventiva’s ability to satisfy in part or full the conditions precedent for additional tranches of the Equity Raise and the conditions with respect to CTTQ, and whether and to what extent the Warrants may be exercised and by which holders, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners’ clinical trials may not support Inventiva's and its partners’ product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva’s clinical trials, Inventiva’s expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH/NASH may not be realized and may not support the approval of a New Drug Application, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners’ control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s and its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollment and completion of Inventiva’s and its partners’ clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Please refer to the Universal Registration Document for the year ended December 31, 2023 filed with the Autorité des Marchés Financiers on April 3, 2024, as amended on October 14, 2024, the Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on April 3, 2024, and the Half-Year Report for the six months ended June 30, 2024 on Form 6-K filed with the SEC on October 15, 2024 for other risks and uncertainties affecting Inventiva, including those described under the caption “Risk Factors”, and in future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements. 1 Non-audited financial information. 2 Press release of October 14, 2024 3 This estimate is based on the Company’s current business plan and excludes any potential milestones payable to or by the Company and any additional expenditures related to the potential continued development of the odiparcil program or resulting from the potential in licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue. The Company may have based this estimate on assumptions that are incorrect, and the Company may end up using its resources sooner than anticipated. 4 Short-term deposits were included in the category “other current assets” in the IFRS consolidated statement of financial position and were considered by the Company as liquid and easily available. 5 The long-term deposit had a two year-term, was accessible prior to the expiration of the term with a notice period of 31 days and was considered as liquid by the Company. 6 Press release of July 18, 2024 Attachment Inventiva - PR - Q3 2024 CA Cash - EN - 11 21 2024 - Final
SANTA CLARA, Calif. (AP) — San Francisco quarterback Brock Purdy took part in some light throwing on Monday after missing his first career game because of an injury and the 49ers are hoping he can return this week. Purdy hurt his throwing shoulder during a loss to Seattle on Nov. 17. Purdy underwent two MRIs last week that showed no structural damage. But Purdy he felt discomfort after making a few throws at practice on Thursday and was shut down for the game at Green Bay on Sunday that San Francisco lost 38-10 . Coach Kyle Shanahan said Monday that Purdy made it through the session without pain and will rest on Tuesday and hopefully be able to return to practice on Wednesday as the Niners prepare to play at Buffalo this coming week. “We rested it throughout the weekend hoping that would help,” Shanahan said. “He threw lighter today to see if that rest helps and the rest did help him. So we’ll see again, going through the same things we did last week. We’re going to let him rest all the way up to Wednesday. We’ll see how it feels on Wednesday and then we’ll take the exact same course throughout the week. Hopefully it responds better this week than it did last week with the rest.” Brandon Allen went 17 for 29 for 199 yards with a touchdown, an interception and a lost fumble in his first start since the 2021 season. Allen would play once again if Purdy is unable to go on Sunday at Buffalo. Purdy wasn't the only star player missing for the 49ers on Sunday with defensive end Nick Bosa missing the game with injuries to his left hip and oblique and left tackle Trent Williams out with an ankle injury. “Just waiting to see how they respond,” Shanahan said. “They didn’t respond great last week. That’s why they weren’t able to go. Nick and Trent are both in the same boat. ... We’ll evaluate as this week progresses and hopefully it turns a better corner than it did last week.” In other injury news, linebacker Dre Greenlaw will return to practice this week for the first time since tearing his Achilles tendon in the Super Bowl last season. Greenlaw will likely need at least a couple of weeks of practice before being able to return to play. Offensive lineman Jon Feliciano will be shut down for the rest of the season after his knee injury didn't fully heal. Feliciano's three-week practice window ended Monday and the Niners decided to keep him on injured reserve instead of activating him. Left guard Aaron Banks, defensive tackle Jordan Elliott and receiver Jacob Cowing all remain in concussion protocol to start this week and their status is unknown. Right guard Dominick Puni (shoulder) and cornerback Deommodore Lenoir (knee) underwent MRIs on Monday and the team is waiting for results. Cornerback Renardo Green (neck) and linebacker Demetrius Flannigan-Fowles (knee) are day to day. Defensive tackle Kevin Givens is expected to return to practice this week after missing the past four games with a groin injury. AP NFL: https://apnews.com/hub/nfl